0
Catégories
Documents disponibles dans cette catégorie (251)
Ajouter le résultat dans votre panier Affiner la recherche
Varenicline / Gillian M. Keating (2010)
Titre : Varenicline : a pharmacoeconimic review of its use as an aid to smoking cessation Type de document : texte imprimé Auteurs : Gillian M. Keating, Auteur ; Katherine, A. Lyseng-Williamson, Auteur Année de publication : 2010 Importance : 19 p. Présentation : tab. Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varénicline
[TABAC] tabagisme:aspect économique:coût du tabagisme:coût pour le fumeurIndex. décimale : TA 6.2.3.2 Autres produits Résumé : Varenicline (Chantix, Champix) is an orally administered alpha4beta2 nicotinic acetylcholine receptor partial agonist that is indicated as an aid to smoking cessation. Well designed clinical trials indicate that varenicline is an effective aid to smoking cessation. During the last 4 weeks of treatment, carbon monoxide-confirmed continuous abstinence rates were generally significantly higher with varenicline than with placebo, bupropion sustained release (SR) or nicotine replacement therapy. Varenicline also reduced cravings, the reinforcing effects of smoking and some withdrawal symptoms. Another well designed trial demonstrated that extending varenicline therapy by an additional 12 weeks helped maintain abstinence in individuals who had quit smoking. Varenicline was generally well tolerated in clinical trials; nausea, the most commonly occurring adverse event, diminished over time. More data are needed regarding the potential for neuropsychiatric events in varenicline recipients. Some of these events may be associated with nicotine withdrawal, rather than varenicline, although neuropsychiatric events have been observed in individuals who continued to smoke whilst receiving varenicline. In modelled cost-effectiveness analyses based on data from clinical trials in participants receiving smoking cessation therapy, 12 weeks' treatment with varenicline was predicted to be cost effective from a healthcare payer perspective in numerous countries. With regard to the incremental costs per QALY or life-year gained, 12 weeks' treatment with varenicline consistently dominated bupropion SR and nicotine replacement therapy and was dominant over or considered cost effective relative to unaided cessation, regular brief counselling or nortriptyline in analyses based on Markov models. In additional modelled analyses from a healthcare payer perspective, administering varenicline for an additional 12 weeks in participants who had successfully quit smoking was estimated to have acceptable incremental costs per QALY gained relative to varenicline for 12 weeks and to dominate other smoking cessation options. Moreover, in Swedish analyses that also included societal costs for production and consumption, the incremental cost per QALY gained for varenicline versus bupropion SR, and for an additional 12 weeks of varenicline therapy versus varenicline for 12 weeks only, was below commonly accepted thresholds of cost effectiveness. A US decision-analytic model from the perspective of various US health insurance plans demonstrated that, after 2 years, varenicline was predicted to dominate bupropion SR, in terms of the incremental cost per additional smoking cessation. Varenicline was also dominant or cost effective versus nicotine replacement therapy, and cost effective versus unaided cessation. Sensitivity analyses demonstrated that the results of cost-effectiveness studies were generally robust to plausible variations in key parameters. In conclusion, varenicline is an effective aid to smoking cessation. Varenicline was generally well tolerated in clinical trials, although more data are needed regarding the potential for neuropsychiatric events. The costs associated with varenicline are offset by direct savings associated with the reduction in smoking-related diseases. Despite their limitations, available pharmacoeconomic analyses from numerous countries support the use of varenicline for 12 or 24 weeks as a cost-effective treatment relative to other smoking cessation therapies in smokers who wish to quit smoking. Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8041 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 005591 TA 6.2.3.2 KEA V Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Varenicline versus transdermal nicotine patch for smoking cessation : results from a randomised, open-label trial Type de document : texte imprimé Auteurs : Henri-Jean Aubin, Auteur ; Alex Bobak, Auteur ; John Britton, Auteur Editeur : Thorax Année de publication : 08/02/2008 Collection : Thorax Importance : 8 p. Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] étude:recherche:recherche clinique:essai clinique randomisé
[TABAC] sevrage tabagique:efficacité du sevrage
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:substitution nicotinique
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varéniclineIndex. décimale : TA 6.2.3 Approche pharmacologique Résumé : La varénicline, un nouveau traitement pour la cessation tabagique, a démontré de manière significative une plus grande efficacité sur le placebo et le bupropion. Une étude a été menée pour comparer un régime de 12 semaines à la varénicline en parallèle avec un régime de 10 semaines d'une thérapie de remplacement nicotinique transcutanée standard pour le sevrage tabagique. En ligne : https://thorax.bmj.com/content/63/8/717.long Format de la ressource électronique : HTML Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=3011 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Virtual reality cue exposure for the relapse prevention of tobacco consumption / Camille Giovancarli (2016)
Titre : Virtual reality cue exposure for the relapse prevention of tobacco consumption : a study protocol for a randomized controlled trial Type de document : document électronique Auteurs : Camille Giovancarli, Auteur ; Eric Malbos, Auteur ; Karine Baumstarck, Auteur Editeur : Springer Année de publication : 2016 Collection : Trials, ISSN 1745-6215 num. 17 Importance : 9 p. Présentation : tab., ill. Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] sevrage tabagique
[TABAC] sevrage tabagique:efficacité du sevrage:rechute
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche psychologique:thérapie cognitivo-comportementale
[TABAC] tabagisme:aspect psychologique:comportementMots-clés : réalité virtuelle. Index. décimale : TA 6.5 Rechutes Résumé : Background:
Successful interventions have been developed for smoking cessation, but the success of smoking relapse prevention interventions has been limited. In particular, cognitive behavioural therapy (CBT) has been hampered by a high relapse rate. Because relapses can be due to the presence of conditions associated with tobacco consumption (such as drinking in bars with friends), virtual reality exposure therapy (VRET) can generate synthetic environments that represent risk situations for the patient in the context of relapse prevention. The primary objective of this study is to evaluate the effectiveness of CBT coupled with VRET, in comparison to CBT alone, in the prevention of smoking relapse. The secondary objectives are to assess the impact of CBT coupled with VRET on anxiety, depression, quality of life, self-esteem and addictive comorbidities (such as alcohol, cannabis, and gambling). A third objective examines the feasibility and acceptability of VR use considering elements such as presence, cybersickness and number of patients who complete the VRET program.
Method/design:
The present study is a 14-month (2 months of therapy followed by 12 months of follow-up), prospective, comparative, randomized and open clinical trial, involving two parallel groups (CBT coupled with VRET versus CBT alone). The primary outcome is the proportion of individuals with tobacco abstinence at 6 months
after the end of the therapy. Abstinence is defined by the total absence of tobacco consumption assessed during a post-test interview and with an apparatus that measures the carbon monoxide levels expired. A total of 60 individuals per group will be included.
Discussion :
This study is the first to examine the efficacy of CBT coupled with VRET in the prevention of smoking relapse. Because VRET is simple to use and has a low cost, this interactive therapeutic method might be easily implemented in clinical practice if the study confirms its efficacyEn ligne : https://doi.org/10.1186/s13063-016-1224-5 Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=9756 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : When smokers move out and non-smokers move in : residential thirdhand smoke pollution and exposure Type de document : texte imprimé Auteurs : Georg E. Matt, Auteur ; Penelope J. E. Quintana, Auteur ; Joy M. Zakarian, Auteur ; Addie L. Fortmann, Auteur Editeur : BMJ Publishing Group Année de publication : 2011 Collection : Tobacco Control num. 20 Importance : 8 p. Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] tabagisme:effet sur l'environnement:pollution
[TABAC] tabagisme:effet sur l'environnement:tabagie
[TABAC] tabagisme:tabagisme passifIndex. décimale : TA 7.9 Fumée tertiaire Résumé : Abstract
Background This study examined whether thirdhand smoke (THS) persists in smokers' homes after they move out and non-smokers move in, and whether new non-smoking residents are exposed to THS in these homes.
Methods The homes of 100 smokers and 50 non-smokers were visited before the residents moved out. Dust, surfaces, air and participants' fingers were measured for nicotine and children's urine samples were analysed for cotinine. The new residents who moved into these homes were recruited if they were non-smokers. Dust, surfaces, air and new residents' fingers were examined for nicotine in 25 former smoker and 16 former non-smoker homes. A urine sample was collected from the youngest resident.
Results Smoker homes' dust, surface and air nicotine levels decreased after the change of occupancy (p<0.001); however dust and surfaces showed higher contamination levels in former smoker homes than former non-smoker homes (p<0.05). Non-smoking participants' finger nicotine was higher in former smoker homes compared to former non-smoker homes (p<0.05). Finger nicotine levels among non-smokers living in former smoker homes were significantly correlated with dust and surface nicotine and urine cotinine.
Conclusions These findings indicate that THS accumulates in smokers' homes and persists when smokers move out even after homes remain vacant for 2 months and are cleaned and prepared for new residents. When non-smokers move into homes formerly occupied by smokers, they encounter indoor environments with THS polluted surfaces and dust. Results suggest that non-smokers living in former smoker homes are exposed to THS in dust and on surfaces.En ligne : https://tobaccocontrol.bmj.com/content/20/1/e1 Format de la ressource électronique : HTML Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8086 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Workplace smoking / Carin Håkansta (2004)
Titre : Workplace smoking : working paper: a review of national and local practical and regulatory measures Type de document : document électronique Auteurs : Carin Håkansta, Auteur Editeur : Genève [Suisse] : International Labour Office Publications (ILO Publications) Année de publication : 2004 Importance : 89 p. Présentation : tab., graph. ISBN/ISSN/EAN : 978-92-2-115720-5 Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] législation:législation antitabac:interdiction de fumer
[TABAC] législation:milieu réglementé:lieu de travail
[TABAC] tabagisme:tabagisme passifIndex. décimale : TA 7.2 Environnement enfumé Résumé : Workplace smoking can be a serious safety and health hazard and a cause of conflict. Promotion and implementation of a smoke-free work environment therefore fall under the ILO’s mandate to create healthy and safe workplaces. This working paper, based to a large extent on an informal survey carried out by ILO SafeWork in 2003, sets out to provide an overview of attitudes, legislation and practices related to smoke-free workplaces in different parts of the world. It could serve as a background paper for further ILO tripartite discussions leading up to a new international instrument.
Because of the rapidly changing nature of the debate and legal frameworks related to workplace smoking, the overview will need to be reviewed and periodically updated. Such exercises may require pooling more examples of enterprise and trade union policies and programmes and undertaking a thorough analysis of existing legislation, policies and best practices.
The working paper has been written within the general framework of preventing psychosocial problems at work. Its purpose is to create a knowledge base for further activities in the area of promoting and implementing smoke-free workplaces and also the SOLVE interactive educational programme on psychosocial issues.Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=9989 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Young adult smokers' neural response to graphic cigarette warning labels Type de document : document électronique Auteurs : Adam E. Green, Auteur ; Darren Mays, Auteur ; Emily Falck, Auteur Editeur : Paris [France] : Elsevier Année de publication : 2016 Langues : Français (fre) Catégories : [DIVERS] anatomie:corps humain:système nerveux:cerveau
[DIVERS] personne:par âge:jeune
[TABAC] économie du tabac:fabrication du tabac:étiquetage:avertissement sanitaire
[TABAC] étudeMots-clés : IRM Résumé : L'étude a examiné la réponse neurale de jeunes adultes fumeurs à des étiquettes d'avertissement graphiques (GWL) sur des paquets de cigarettes utilisant l'imagerie par résonance magnétique fonctionnelle (IRMf).
Les méthodes
Dix - neuf jeunes fumeurs adultes ( M âge 22,9, 52,6% d' hommes, 68,4% non-blanc, M 4.3 cigarettes / jour) terminé pré-scan, les mesures d' auto-évaluation de la démographie, le tabagisme comportement et dépendance à la nicotine , et une séance de balayage IRMf . Pendant la session de numérisation, les participants ont visualisé des images de paquets de cigarettes (totalisant 64 stimuli, visualisées 4 s chacune) en fonction de l’étiquette d’avertissement (contrôle visuel ou occlus) et de la Les participants ont déclaré être motivés à cesser de fumer (MTQ) en réponse à chaque image en utilisant un bouton-poussoir. Oxygénation du sang dans le cerveau entier Les images fonctionnelles dépendantes du niveau (BOLD) ont été acquises pendant la tâche.
Résultats
Les GWL produisaient un MTQ autodéclaré beaucoup plus élevé que les avertissements de contrôle ( p < 0,001). Les données d'imagerie indiquent une activation neuronale plus forte en réponse aux GWL que les alertes de contrôle à un seuil p < 0,001 corrigé en grappes dans le cortex préfrontal médian , l' amygdale , le lobe temporal médial et le cortex occipital . Il n'y avait pas de différences significatives en réponse aux avertissements sur les paquets de cigarettes de marque par rapport aux paquets de cigarettes ordinaires.
Conclusions
Dans cet échantillon de jeunes fumeurs adultes, les GWL ont favorisé l'activation neuronale dans les régions du cerveau impliquées dans la prise de décision cognitive et affective et la formation de la mémoire, et les effets des GWL ne différaient pas sur les emballages de cigarettes ordinaires ou de marque. Ces résultats complètent d'autres études récentes de neuroimagerie menées sur des sujets ayant trait à des fumeurs âgés et à des adolescents en démontrant des schémas similaires d'activation neuronale en réponse aux GWL chez les jeunes fumeurs adultes.
En ligne : https://www.sciencedirect.com/science/article/pii/S2352853216300013?via%3Dihub Format de la ressource électronique : HTML, PDF Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8731 Aucun avis, veuillez vous identifier pour ajouter le vôtre !